Pharmacological management of narcolepsy with and without cataplexy

@article{Kallweit2017PharmacologicalMO,
  title={Pharmacological management of narcolepsy with and without cataplexy},
  author={Ulf Kallweit and Claudio L. A. Bassetti},
  journal={Expert Opinion on Pharmacotherapy},
  year={2017},
  volume={18},
  pages={809 - 817},
  url={https://api.semanticscholar.org/CorpusID:1906751}
}
This review provides an overview of the temporal available treatment options for narcolepsy (type 1 and 2) in adults, including authorization status by regulatory agencies, as well as combination therapies.
View on Taylor & Francis
ncbi.nlm.nih.gov
48 Citations
Highly Influential Citations
3
Background Citations
14
Methods Citations
1
Results Citations
1

48 Citations

Narcolepsy — clinical spectrum, aetiopathophysiology, diagnosis and treatment

Current understanding of how genetic, environmental and immune-related factors contribute to a prominent orexin signalling deficiency in patients with NT1 are focused on, along with uncertainties concerning the ‘narcoleptic borderland’, including narcolepsy type 2 (NT2).

Pitolisant for the treatment of cataplexy in adults with narcolepsy

Pitolisant, a histamine H3-receptor antagonist/inverse agonist, has demonstrated efficacy for the reduction of both cataplexy and EDS in patients with narcolepsy, including patients who experience frequent catapLexy attacks.

Clinical Characteristics of Cataplectic Attacks in Type 1 Narcolepsy

There is no cure for narcolepsy, but cataplexy can be well-managed with current and promising new treatment options on the horizon.

Evaluating pitolisant as a narcolepsy treatment option

Clinical trials suggest that pitolisant administered at a dose of ≤36 mg/day is an effective treatment option for narcolepsy, reducing EDS and cataplexy.

Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy

The review confirmed the effectiveness of pitolisant in treating major clinically relevant narcolepsy symptoms, including cataplexy, as compared to placebo and revealed a safe profile when compared with placebo and active comparators.

Narcolepsy treatment: pharmacological and behavioral strategies in adults and children

The available therapeutic options for narcolepsy are reviewed, including symptomatic pharmacological treatments as well as behavioral and psychosocial interventions that could help clinicians improve the quality of life of patients with nar colepsy in adulthood and childhood.

Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications.

Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy.

Narkolepsie im Erwachsenenalter: De fi nition, Ätiologie und Behandlung Narcolepsy in adults: De fi nition, etiology and treatment

The management of narcolepsy is usually life-long and includes non-pharmacological approaches and a symptomatic pharmacological treatment.

Pitolisant: A Review in Narcolepsy with or without Cataplexy

With minimal abuse potential and offering the convenience of oral, once-daily administration, pitolisant extends the range of approved treatment options available to adult patients with narcolepsy with or without cataplexy.

89 References

EFNS guidelines on management of narcolepsy

A task force composed of the leading specialists of narcolepsy in Europe conducted an extensive review of pharmacological and behavioral trials available in the literature to reinforce the use of those drugs evaluated in randomized placebo‐controlled trials and to reach a consensus, as much as possible, on theUse of other available medications.

The clinical spectrum of narcolepsy with cataplexy: a reappraisal

Analysis of co‐occurring symptoms in patients with narcolepsy revealed two symptom complexes: EDS, cataplexy, automatic behaviors; and sleep paralysis, hallucinations, parasomnias, which supports the hypothesis of a distinct pathophysiology of singleNarcoleptic symptoms.

Treatment of narcolepsy and other hypersomnias of central origin.

The strengths and limitations of the available evidence regarding treatment of narcolepsy and other hypersomnias of central origin are discussed, and key information about safety of these medications is summarized.

Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy

Transient Impact of Rituximab in H1N1 Vaccination–associated Narcolepsy With Severe Psychiatric Symptoms

Remarkable but short-lasting effect of RXB in narcolepsy is intriguing as it could imply that there is still ongoing B cell–mediated autoimmune response possible contributing to symptoms in narCOlepsy.

Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings.

It is noteworthy, therefore, that the central biochemical changes induced by GHB also appear comparable to those found naturally in narcolepsy.

A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy

A remarkable clinical observation was made in a patient suffering from narcolepsy with cataplexy that may add to the understanding of the pathophysiology of this disorder, which is considered to be an autoimmune disorder with T-cell involvement.

Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset

A clear improvement in the frequency and severity of cataplexy was obtained and the importance of early diagnosis of narcolepsy, which once treated quickly may modify its long‐term outlook is pointed to.

Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials.

CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice

It is demonstrated that cytotoxic CD8 T cells, but not Th1 CD4 cells, are able to target and destroy orexinergic neurons, and the potential role of CTLs as final effectors of the immunopathological process in narcolepsy is demonstrated.
...